What Black Women Need to Know: WHO’s New Guideline on GLP-1 Medicines for Obesity Care

Obesity care is changing—and the World Health Organization (WHO) just made it official. For the first time, the WHO has released a global guideline on the use of GLP-1 medicines to treat obesity in adults. But…What does this mean for Black women? What should you know before starting a conversation with your healthcare provider?

Why This Guideline Matters

Obesity is now recognized as a chronic, complex disease—not just a matter of willpower or lifestyle. For too long, the narrative around obesity has focused on personal responsibility, ignoring the social, economic, and biological factors that make managing weight so challenging—especially for Black women. The WHO’s new guideline is a game-changer, positioning GLP-1 medicines as a legitimate tool for long-term obesity care. But it’s not a quick fix—these medications are recommended only as part of a comprehensive, lifelong plan that centers your overall well-being, not just the number on the scale.

Understanding GLP-1 Medicines

GLP-1 medicines (like semaglutide and liraglutide) are a newer class of drugs originally developed to help manage type 2 diabetes. They work by mimicking a natural hormone in your body that helps regulate blood sugar and appetite. In recent years, these medications have shown promise for helping people with obesity lose weight and improve key health markers. However, they are potent drugs—and not appropriate for everyone.

Who Qualifies for GLP-1 Treatment?

According to the WHO, GLP-1 medicines are recommended for adults aged 19 and older with a Body Mass Index (BMI) of 30 or higher. Pregnant women are excluded from this recommendation due to limited safety data. It’s important to note: GLP-1s are also on the WHO’s Essential Medicines List, but only for adults with type 2 diabetes and existing heart or kidney disease. Meeting the eligibility criteria is just the first step; the treatment must be part of a broader, structured care plan.

Medication + Intensive Behavioral Therapy: A Dual Approach

The WHO’s guideline is straightforward. Providers must pair GLP-1s with Intensive Behavioral Therapy (IBT)—not just prescribed and forgotten. IBT is a structured program that typically involves 14–16 sessions over six months. These sessions are designed to help you develop healthier eating habits, increase physical activity, and address the emotional and psychological aspects of weight management. This approach recognizes that lasting change comes from ongoing support and lifestyle changes, not from medication alone.

Why does this matter? Because research shows that combining medication with behavioral support leads to better, more sustainable results. The medication can help manage hunger and cravings, while IBT provides the tools and accountability you need to make meaningful changes.

Ongoing Monitoring and Safety

GLP-1 treatment requires regular follow-ups with your healthcare provider. This includes tracking weight, blood pressure, and blood sugar, and monitoring for side effects. These medications have common side effects, including nausea, vomiting, diarrhea, or constipation, while rare but serious risks include pancreatitis or gallbladder disease. Success is measured not just by pounds lost, but by improved health markers—like lower blood pressure or cholesterol—and overall quality of life. The WHO also emphasizes the importance of monitoring for health equity: Who is—and isn’t—getting access to these treatments?

The Equity Challenge: Barriers for Black Women

Access to these medicines is a significant concern. High costs and inconsistent insurance coverage mean many Black women may face extra barriers. In the U.S., systemic racism, provider bias, and social determinants of health already make it harder for Black women to access quality care. The WHO calls for an ecosystem of care—fair pricing, unbiased providers, and community support—to ensure everyone can access safe, effective treatment. Without intentional advocacy and policy change, there’s a risk that only those with financial means or the right insurance will benefit from these advances.

For Black women, who are disproportionately affected by obesity and related health conditions, these barriers are especially urgent. That’s why community advocacy and culturally competent care are critical. We need to demand that our voices are heard in policy discussions, research priorities, and healthcare delivery.

Take Action: Advocate for Your Health

• Talk to your healthcare provider about your options and holistic health needs. Ask if you meet the criteria for GLP-1 therapy and what support programs are available.
• Ask questions about eligibility, side effects, monitoring, and how behavioral therapy is integrated into care.
• Share your experiences and advocate for equitable access within your circles and in the Rooted in Violet community.
• Support local and national efforts to push for insurance coverage, fair pricing, and culturally competent care.

Empowerment Through Knowledge

Your health journey is unique. Stay informed, stay empowered, and let’s keep pushing for fair, culturally competent care for all Black women. The new WHO guideline is a step forward, but real change will come when every woman has access to the tools, support, and advocacy she needs to thrive.

For more resources, community support, and the latest updates, join us at Rooted in Violet & Co.